OLATEC THERAPEUTICS LLC
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.olatec.com
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
- Conditions
- GoutGout FlareArthritisGout AttackAcute Gout FlareJoint PainGouty Arthritis
- Interventions
- Other: Placebo Tablet
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 300
- Registration Number
- NCT05658575
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈArizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona, United States
πΊπΈArizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa, Mesa, Arizona, United States
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
- Conditions
- Cytokine Release SyndromeCovid19
- Interventions
- Drug: placebo capsules
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 49
- Registration Number
- NCT04540120
- Locations
- πΊπΈ
Las Vegas Medical Research, LLC, Las Vegas, Nevada, United States
πΊπΈInvesclinic U.S. LLC, Fort Lauderdale, Florida, United States
πΊπΈC&R Research Services USA, Houston, Texas, United States
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 2
- Registration Number
- NCT03595371
- Locations
- π³π±
Radboudumc, Nijmegen, Netherlands
Study of Dapansutrile Capsules in Heart Failure
- Conditions
- Systolic Heart Failure
- Interventions
- Drug: Placebo capsules
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03534297
- Locations
- πΊπΈ
Virginia Commonwealth University - Pauley Heart Center, Richmond, Virginia, United States
Phase 1 Safety and PK Study of OLT1177 Capsules
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo CapsulesDrug: OLT1177 Capsules
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 35
- Registration Number
- NCT02134964
- Locations
- πΊπΈ
J&S Studies, Inc, College Station, Texas, United States
Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
- Conditions
- PainOsteoarthritis
- Interventions
- Drug: Placebo GelDrug: OLT1177 Gel
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 202
- Registration Number
- NCT02104050
- Locations
- πΊπΈ
Achieve Clinical Research, LLC, Birmingham, Alabama, United States
πΊπΈAvail Clinical Research, DeLand, Florida, United States
πΊπΈHealth Awareness, Inc., Jupiter, Florida, United States
Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: OLT1177 GelOther: Placebo gel
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 79
- Registration Number
- NCT01768975
- Locations
- πΊπΈ
Wake Research Associates, Raleigh, North Carolina, United States
πΊπΈAvail Clinical Research, DeLand, Florida, United States
πΊπΈMiami Research Associates, South Miami, Florida, United States
Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo gelDrug: OLT1177 Gel
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Olatec Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01636141
- Locations
- πΊπΈ
J&S Studies, Inc, College Station, Texas, United States